Literature DB >> 21103680

Hemodynamic assessment in the critically ill patient.

Paulo Novis Rocha1, Jorge Arnaldo Valente de Menezes, José Hermógenes Rocco Suassuna.   

Abstract

A growing fraction of the clinical duties of Nephrologists is undertaken inside intensive care units. While assessing patients with acute renal failure in the context of circulatory collapse, which are also edematous and/or with impaired gas exchanges, the Nephrologist must decide between two opposing therapies: 1) remove volume with the aid of dialysis or diuretics to improve the edematous state; 2) volume expand to improve hemodynamics. To minimize the odds of making incorrect choices, the Nephrologist must be familiar with the tools available for determining the adequacy of volume status and for invasive hemodynamic monitoring in the critically ill patient. In this manuscript, we will briefly review the physiology of extra cellular fluid volume regulation and then tackle the issue of volume status assessment, based on clinical and hemodynamic criteria.

Entities:  

Mesh:

Year:  2010        PMID: 21103680

Source DB:  PubMed          Journal:  J Bras Nefrol        ISSN: 0101-2800


  3 in total

1.  [Blood pressure monitoring - Status quo and future : A contribution to the personalized medicine].

Authors:  L Engelmann; S Kunig; H Kunig
Journal:  Med Klin Intensivmed Notfmed       Date:  2016-07-12       Impact factor: 0.840

2.  Association of preoperative anxiety and depression symptoms with postoperative complications of cardiac surgeries.

Authors:  Hélen Francine Rodrigues; Rejane Kiyoma Furuya; Rosana Aparecida Spadoti Dantas; Alfredo José Rodrigues; Carina Aparecida Marosti Dessotte
Journal:  Rev Lat Am Enfermagem       Date:  2018-11-29

3.  Prediction of hemodynamic tolerance of intermittent hemodialysis in critically ill patients: a cohort study.

Authors:  Rogerio da Hora Passos; Juliana Ribeiro Caldas; Joao Gabriel Rosa Ramos; Erica Batista Dos Santos Galvão de Melo; Marcelo Augusto Duarte Silveira; Paulo Benigno Pena Batista
Journal:  Sci Rep       Date:  2021-12-08       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.